Kidney and pancreas transplantation by Wynn, James J. et al.
American Journal of Transplantation 2004; 4 (Suppl. 9): 72–80
Blackwell Munksgaard
Blackwell Munksgaard 2004
Kidney and pancreas transplantation
James J. Wynna,∗, Dale A. Distantb, John D.
Pirschc, Douglas Normand, A. Osama Gabere,
Valarie B. Ashbyf and Alan B. Leichtmanf
aMedical College of Georgia, Augusta, GA;
bState University of New York Health Science Center at
Brooklyn, Brooklyn, NY;
cUniversity of Wisconsin-Madison, Madison, WI;
dOregon Health and Science University, Portland, OR;
eUniversity of Tennessee, Knoxville, TN;
fScientific Registry of Transplant Recipients/University of
Michigan, Ann Arbor, MI
∗Corresponding author: James J. Wynn,
jwynn@mail.mcg.edu
Data from the Scientific Registry of Transplant Recip-
ients offer a unique and comprehensive view of US
trends in kidney and pancreas waiting list character-
istics and outcomes, transplant recipient and donor
characteristics, and patient and allograft survival. Im-
portant findings from our review of developments dur-
ing 2002 and the decade’s transplantation trends ap-
pear below.
The kidney waiting list has continued to grow, increas-
ing from 47 830 in 2001 to 50 855 in 2002. This growth
has occurred despite the increasing importance of liv-
ing donor transplantation, which rose from 28% of to-
tal kidney transplants in 1993 to 43% in 2002.
Policies and procedures to expedite the allocation of
expanded criteria donor (ECD) kidneys were developed
and implemented during 2002, when 15% of deceased
donor transplants were performed with ECD kidneys.
Unadjusted 1- and 5-year deceased donor kidney al-
lograft survivals were 81% and 51% for ECD kidney
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recipients, and 90% and 68% for non-ECD kidney re-
cipients, respectively.
Although more patients have been placed on the si-
multaneous kidney-pancreas waiting list, the number
of these transplants dropped from a peak of 970 in 1998
to 905 in 2002. This decline may be due to competition
for organs from increasing numbers of isolated pan-
creas and islet transplants.
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Introduction
This overview of kidney and pancreas transplantation fo-
cuses on developments during 2002 and provides an im-
portant summary of trends over the past decade. The
transplant process is examined first through analyses of
waiting list characteristics and outcomes, followed by as-
sessments of transplant recipient characteristics and of
patient and allograft survival. The characteristics of ex-
panded criteria donors and the unique outcomes of pa-
tients receiving expanded criteria donor kidney transplants
is described, followed by sections addressing simultane-
ous kidney-pancreas, pancreas after kidney, and isolated
pancreas transplantation.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2003 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Trans-
plant data: sources, collection, and caveats’ and ‘Ana-
lytical approaches for transplant research’, explain the
methods of data collection, organization, and analysis that
serve as the basis for this article (1,2). Additional detail
on the methods of analysis may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Kidney Transplantation
Kidney transplantation continues to be recognized as the
treatment of choice for medically suitable patients with
end-stage kidney disease, leading to a continued and
marked growth in the size of the kidney transplant wait-
ing list (Figure 1). The particular advantage of pre-emptive
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Figure 1: Growth in the waiting list for deceased donor kidneys,
1993–2002.
kidney transplantation—prior to the initiation of dialysis—is
now well-recognized and is being progressively exploited,
especially by patients receiving living donor kidney trans-
plants (3,4).
The kidney transplant waiting list
The number of candidates on the kidney waiting list has
grown steadily, increasing from 47 830 in 2001 to 50 855
in 2002. Almost 75% of the increase occurred among pa-
tients 50 years of age or older, who now constitute over
50% of the total waiting list, compared to only 34% in
1993 (Figure 2). African-Americans continued to be dis-
proportionately represented on the waiting list. African-
Americans now represent 37% of the waiting list, a similar
proportion to their 38% of the dialysis population overall
(5). Of all candidates on the waiting list, 19% had received
a previous kidney transplant, while 34% had a peak panel
reactive antibody (PRA) of 10% or greater. As would be
expected, given the relatively static deceased donor kid-
ney supply and increase in the waiting list size, waiting
times continued to increase steadily. Twenty-five per cent
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Source: 2003 OPTN/SRTR Annual Report, Table 5.1  
Figure 2: Percentage on the kidney waiting list, by age group,
1993–2002.
by 341 days, compared to 297 days in 1998 and 235 days
in 1993.
Recognition of the clear survival advantage obtained by pa-
tients undergoing kidney transplantation as compared to
remaining on the waiting list—and of the adverse impact
of time on dialysis on transplant survival—underscores the
importance of equity in kidney transplant waiting time.
Current OPTN/UNOS kidney allocation policies acknowl-
edge children’s and adolescents’ disproportionate need for
transplantation. As a result of the increased priority af-
forded them, patients younger than 18 years of age en-
joy shorter waiting times. In contrast, African-American,
Asian, and other nonwhite candidates experience longer
waiting times. The point at which 25% of new registrants
were transplanted could be calculated only for those minor-
ity candidates registered in 2001, with the 25th percentile
of time to transplant being 268 days for whites, 630 days
for African-Americans, 626 days for Asians and 483 days
for other nonwhite patients. Other factors resulting in ap-
parently prolonged waiting times as measured by 25th
percentile of time to transplant included Hispanic-Latino
ethnicity (442 vs. 326 days for non-Hispanic/non-Latino in
2002), blood type B or O (521 or 462, respectively, vs.
223 days for blood type A), having received a previous
transplant (430 vs. 328 days), and anti-HLA sensitization
(1018 days for peak PRA of 80% or greater, compared to
only 288 days for unsensitized candidates in 2000).
These observations were supported by a multivariate anal-
ysis of transplant waiting time recently performed by the
SRTR. After adjusting for recipient age, gender, cause of
ESRD, blood type, race, ethnicity, current PRA, source
of insurance payment, dialysis modality, transplant num-
ber, previous transfusions, HLA type, and organ procure-
ment organization (OPO), this study showed that pa-
tients who were over 50 years of age, African-American,
Hispanic, B blood type, sensitized against HLA, or had un-
dergone a previous transplant were markedly less likely to
be transplanted (Table 1). Table 2 shows the distribution of
these factors among wait-listed and transplanted patients
in 2002. Interestingly, the apparent prolongation in waiting
time suffered by Asian-Americans was not seen when the
model incorporated adjustments for HLA and OPO (6,7).
Death rates per 1000 patient years at risk among wait-
listed candidates have tended to remain stable, ranging
from 66 to 82 over the past 4 years. As expected, death
rates increased with age but tended to be lower among
nonwhite candidates.
Kidney transplant recipients
There was modest growth in deceased donor kidney trans-
plantation in 2002, an increase of 3% (from 8065 to 8287)
in contrast to the 1% increase seen the year before. At the
same time, the marked growth in living donor kidney trans-
plantation observed from 2000 to 2001 (11%) appears to
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Table 1: Recipient factors resulting in prolonged kidney transplant
waiting times, 1994–2000
Relative rate Reference
Factor of transplantation group
Age 50–64 years 0.912 Age 35–49 years
Age 65 or greater 0.827 Age 35–49 years
Blood type B 0.850 Type O
African-American race 0.766 White
Hispanic/Latino ethnicity 0.904 Non-Hispanic/
Non-Latino
Current PRA 10–40% 0.707 PRA 0–9%
Current PRA 41–79% 0.483 PRA 0–9%
Current PRA ≥ 80% 0.413 PRA 0–9%
Having received No previous
previous transplant 0.559 transplant
p-values for all rates < 0.0001 vs. reference group. Source: Wolfe
et al. 2001 (6).
Table 2: Distribution of recipient factors resulting in increased kid-
ney waiting time among waiting and transplanted patients, 2002
Deceased donor
Waiting Recipients Living donor
Factor list (%) (non-ECD)% transplants (%)
Age 50–64 years 40.2 37.4 30.8
Age 65 or greater 12.5 9.9 8.3
ABO Type B 16.9 12.1 12.9
African-American race 36.5 29.1 13.9
Hispanic/Latino ethnicity 15.7 14.0 12.6
Peak PRA 10–79% 19.5 21.4 14.8
Peak PRA ≥ 80% 14.0 9.9 2.7
Having received
previous transplant 18.6 14.5 10.7
Source: 2003 OPTN/SRTR Annual Report, Tables 5.1, 5.4a, 5.4c.
have slowed, with only a 4% increase in 2002. Over the
decade, however, living donation has become much more
common, with living donor kidney transplants increasing
from 28% of kidney transplants performed in 1993 to 43%
in 2002 (Figure 3).
In general, recipients in 2002 were older, with the percent-
ages of deceased donor transplant recipients aged 50–
64 years and 65 years and older having increased from
29% and 5% (1993) to 37% and 10% (2002), respectively.
Among all recipients of living donor kidneys, recipients
aged 50–64 years increased from 17% to 31% from 1993
to 2002, while recipients 65 years and older increased from
2% to 8%.
With the principal exceptions of retransplantation/graft fail-
ure and renovascular disease, the rank order of the etiolo-
gies of kidney failure remained relatively constant through-
out the decade. Recipients listed with a primary diagnosis
of retransplantation or graft failure increased from 1% to
13% of deceased donor kidney transplants, and from 0.9%
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Source: 2003 OPTN/SRTR Annual Report, Table 1.8 .
Figure 3: Kidney transplants performed in the USA, by year and
donor source, 1993–2002.
percentage with renovascular and other vascular causes in-
creased from 0.6% to 5% of deceased donor transplants,
and from 0.5% to 4% of living donor transplants.
Approximately 16% of deceased donor transplants were
zero-antigen mismatched, a figure that has been stable
since 1995. The vast majority of deceased donor trans-
plants were mismatched at three or more antigens (73%
in 2002). Only 4% of deceased donor and 1% of living
donor transplants were performed in patients whose PRA
at transplant was 80% or greater.
Concern regarding potential inequities in the current kidney
allocation system has led the OPTN to modify the weight
assigned to HLA identity in the kidney allocation system.
In particular, African-American and Asian recipients—who
suffer longer waiting times for transplantation—have been
found to receive a much lower percentage of zero HLA mis-
matched kidneys (6% and 5% of transplants, respectively,
compared to 16% for whites) and to receive relatively more
kidneys with higher degrees of mismatch (61% and 69%
with HLA mismatch of four or greater, respectively, com-
pared to 46% for whites) (8). Further analysis by the SRTR
showed that identity for HLA A and HLA B no longer ap-
peared to significantly impact graft survival, and projected
that elimination of HLA B from the kidney allocation system
would assist in addressing the lower rate of transplantation
among African-American candidates (9).
Outcomes following kidney transplantation
Mean unadjusted kidney graft survival rates progressively
improved between 1992 and 2001 for recipients of first de-
ceased donor and first living donor kidney transplants. One-
year deceased donor graft survival increased from 84% in
1992 to 89% in 2001, while 1-year living donor graft survival
improved from 92% to 94%. Five- and 10-year deceased
donor kidney graft survival rates were 66% and 36%,
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Source: 2003 OPTN/SRTR Annual Report,Table 5.9a. 
The cohort is transplants performed during the 1996-1997 year. 
Figure 4: Graft survival 5 years after deceased donor kidney trans-
plantation, by donor age.
respectively. Living donor graft survival rates reached 79%
at 5 years and 55% at 10 years.
Deceased donor recipients—graft survival. Unadjusted de-
ceased donor kidney allograft survival rates were higher
among recipients who are under 50 years of age, Asian or
white, and Hispanic/Latino, and were lower for those with
blood type B and for individuals with prior kidney trans-
plants. The highest unadjusted 5-year deceased donor al-
lograft survival rates were among recipients with a pri-
mary diagnosis of polycystic kidneys (76%), neoplasm
(73%), congenital and rare familial and metabolic disor-
ders (73%), glomerular diseases (68%), or tubular and in-
terstitial diseases (68%). Lesser unadjusted 5-year allo-
graft survival rates were found among recipients with a
primary diagnosis of retransplant/graft failure (62%), hy-
pertension/nephrosclerosis (62%), diabetes (61%) or ren-
ovascular and other vascular diseases (60%). PRA levels
below 10% at the time of transplant were associated with
superior deceased donor allograft survival at each of the
time intervals tested. At the fifth post-transplant year, this
translated into unadjusted deceased donor allograft sur-
vival rates of 67%, 62%, and 58% for PRAs of 0–9%,
10–79%, and 80% or higher, respectively. Dialysis within
the first week of transplantation was an adverse predictor
of deceased donor allograft success at 3 months, 1 year,
3 years, and 5 years. By 5 years, those without post-
transplant dialysis had a deceased donor allograft survival
rate of 71%, whereas those who had received dialysis
during the first post-transplant week demonstrated 51%
survival.
Donor ages of 49 years and younger were associated with
higher unadjusted deceased donor allograft survival rates.
Unadjusted 5-year deceased donor allograft survival in-
creased steadily with decreasing donor age, from a low
of 44% for donors aged 65 years and older, to 58% for
donors aged 50–64, to 65% at 35–49, to 72% between 18
and 34, and to 73% for donors 11–17 years old (Figure 4).
Organs from the youngest pediatric deceased donors were
associated with somewhat shorter survival than that seen
for organs from deceased donors aged 11–17 years. De-
ceased donors aged 6–10, 1–5, and younger than 1 year
had 5-year deceased donor allograft survival rates of 66%,
66%, and 58%, respectively. The relative risk of kidney
allograft failure, adjusted for recipient age, is shown in
Table 3.
The level of HLA match also influences deceased donor
kidney allograft survival. By 5 years post-transplant, the
highest unadjusted deceased donor allograft survival rate
(72%) was seen for recipients of zero HLA mismatched
kidney transplants. Intermediate 5-year deceased donor al-
lograft survival rates of 70%, 68%, and 68% were seen
with one, two, and three HLA mismatches, and the low-
est rates, 63%, 61%, and 60%, were seen with four, five,
and six HLA mismatched transplants, respectively. There
was no consistent relationship between transplant center
volume and deceased donor allograft survival rates.
Deceased donor recipients—patient survival. Unadjusted
1-year patient survival rates have remained stable over
the past decade at approximately 94% for recipients of
deceased donor kidneys and 97% for recipients of living
donor kidneys. Five-year patient survival of deceased and
living donor kidney recipients were 81% and 90%, respec-
tively, while 10-year patient survival rates of the same cat-
egories of recipients were 58% and 77%.
Five-year unadjusted patient survival was highest for recip-
ients younger than 35 years; survival rates fell steadily with
increasing age. Asians exhibited a higher deceased donor
5-year unadjusted patient survival rate (87%) than whites
(81%) and African-Americans (79%). Five-year unadjusted
patient survival among those of Hispanic/Latino ethnicity
(85%) was higher than that seen among those with non-
Hispanic/non-Latino ethnicity (81%).
Table 3: Relative rate of graft failure for donor age, 1995–2001
Donor ages Relative





65 + 2.33 <0.0001
42 276 deceased donor kidneys transplanted between 3/6/95
and 6/30/01, Cox proportional hazards model adjusted for NHBD,
donor hypertension, donor diabetes, donor creatinine, donor
race, recipient age, recipient sex, recipient race, cause of ESRD,
HLA mismatch, cold ischemia time, PRA, year of transplant, ABO
compatibility.
Source: SRTR analysis.
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Many of the other factors that influence graft survival
similarly affect patient survival. The highest unadjusted
5-year deceased donor patient survival rates were achieved
by recipients with primary diagnoses of congenital and
rare familial and metabolic disorders (89%), polycystic
kidney disease (88%), glomerular diseases (87%), tubu-
lar and interstitial diseases (86%), and neoplasm (82%).
Lesser unadjusted 5-year patient survival rates were
found among recipients with primary diagnoses of reno-
vascular and other vascular diseases (80%), hyperten-
sion/nephrosclerosis (80%), and diabetes (69%). PRA lev-
els below 10% at the time of transplant are associated with
higher deceased donor patient survival rates at each of the
time intervals tested. At the fifth post-transplant year, un-
adjusted deceased donor patient survival rates were 81%
for recipients with PRAs between 0% and 9%, and 80%
and 75% for PRAs of 10–79% and 80% or higher, respec-
tively. Dialysis within the first week of transplantation was
an adverse predictor of deceased donor patient survival
at each time interval. Five years following transplantation,
those without dialysis had an unadjusted deceased donor
patient survival rate of 83%, whereas those with dialysis in
the first post-transplant week had a survival rate of 73%.
In general, organs from donors aged 49 years or younger
were associated with superior unadjusted deceased donor
patient survival rates. Unadjusted 5-year patient survival
dropped from a range of 81–88% for recipients of kid-
neys from deceased donors aged 49 years or younger, to
75% for recipients of kidneys from deceased donors 50–
64 years old, and to 64% for recipients of kidneys from
deceased donors age 65 years or older.
Living donor recipients—graft survival. The highest un-
adjusted 5-year living donor allograft survival rates were
demonstrated among recipients with primary diagnoses of
polycystic kidneys (87%), congenital and rare familial and
metabolic disorders (83%), and glomerular diseases (80%).
Lesser unadjusted 5-year living donor allograft survival
rates were found among recipients with primary diagnoses
of diabetes (76%), retransplant/graft failure (76%), neo-
plasms (77%), hypertension/nephrosclerosis (73%), and
renovascular and other vascular diseases (72%). PRA lev-
els at the time of transplant that were below 10% were as-
sociated with higher living donor allograft survival at each
of the time intervals tested, but differences were small by
the fifth post-transplant year. Dialysis within the first week
of transplantation was a strong adverse predictor of living
donor allograft outcomes at each time interval. By 5 years,
those without dialysis had a living donor allograft survival
rate of 79%, whereas those who had required dialysis (only
6% of the sample) demonstrated 45% survival.
Pediatric unadjusted living donor 5-year allograft survival
ranged from a low of 72% among recipients 11–17 years
old to a high of 89% for recipients younger than 1 year old.
Asians, whites, Hispanics/Latinos, and males had higher
living donor kidney allograft survival at 3 years, while those
with blood type B exhibited lower survival rates. Adult un-
adjusted 5-year allograft survival ranged from a low of 72%
among recipients 65 years and older to a high of 81% for re-
cipients 35–49 years old. Individuals with prior kidney trans-
plants had worse unadjusted living donor allograft survival
at each time point tested. At 5 years post-transplant, recip-
ients of living donor kidney transplants who had received a
prior transplant exhibited a 72% unadjusted survival rate,
compared to 79% for those who had not.
The level of HLA match and the relationship between donor
and recipient also influenced living kidney transplant sur-
vival. At 5 years post-transplant, the highest unadjusted
living donor kidney allograft survival rate, 87%, was seen
for recipients of zero HLA mismatched transplants. Among
mismatched living donor kidney recipients, however, there
was no relationship between the level of mismatch and
5-year allograft survival, which ranged from 76% to 80%.
The highest 5-year living donor allograft survival, 82%, was
seen when the donor was a sibling. Donations by parents
and children resulted in identical 76% unadjusted 5-year
allograft survival, while other related donors achieved a
79% success rate. Spousal and other unrelated living do-
nation resulted in 5-year allograft survival rates of 76.7%
and 77.4%, respectively.
Living donor recipients—patient survival. Five-year unad-
justed patient survival among recipients of living donor
kidney transplants was highest for those younger than
35 years of age. Five-year survival remained above 90%
until age 50–64 years, when it dropped to 84%. There was
a further decrease to 77% for those aged 65 years and
older. Asians had a higher living donor 5-year unadjusted
patient survival rate (94%) than whites (90%) and African-
Americans (88%). The 5-year unadjusted patient survival
rate among Hispanic/Latino recipients (93%) was higher
than that of non-Hispanic/non-Latino recipients (90%). Un-
adjusted 5-year patient survival ranged from 90% (blood
type O) to 94% (type AB), and was 90% for females and
91% for males.
The highest unadjusted 5-year survival of recipients of liv-
ing donor transplants was achieved by those with primary
diagnoses of congenital and rare familial and metabolic dis-
orders (96%), glomerular diseases (94%), polycystic kid-
ney disease (92%), neoplasm (93%), tubular and intersti-
tial diseases (91%), and renovascular and other vascular
diseases (91%). The lowest unadjusted 5-year patient sur-
vival rates were found among recipients with primary di-
agnoses of hypertension/nephrosclerosis (86%), and dia-
betes (82%). PRA levels at the time of transplant that are
below 10% were not associated with superior living donor
patient survival. Dialysis within the first week of trans-
plantation was an adverse predictor of living donor patient
survival at each time interval. By 5 years, those without
dialysis had an unadjusted living donor patient survival rate
of 91%, whereas the patient survival of those with dialysis
in the first post-transplant week was 81%.
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Patient survival among recipients of zero mismatched liv-
ing donor kidneys was 95% at 5 years. Five-year patient
survival at other levels of mismatch ranged from 88% to
90%. As with graft survival, there was no relationship be-
tween level of HLA mismatch and patient survival among
recipients of mismatched living donor kidneys. There was
also no relationship between transplant center volume and
living donor patient survival rates. The highest 5-year living
donor patient survival, 94%, was seen when the donor
was a parent. Five-year patient survival was 92% when
the living donor was a sibling, 82% for living donation by
an offspring, and 93% when from another category of
relative. Spousal and other unrelated living donation re-
sulted in 5-year patient survival rates of 87% and 89%,
respectively.
Expanded Criteria Donor Kidney
Transplantation
In an attempt to encourage and facilitate deceased donor
transplantation, policies and procedures to identify and ex-
pedite the allocation of kidneys with unfavorable donor
characteristics were developed and implemented by the
OPTN during 2002. These expanded criteria donor (ECD)
kidneys are defined as kidneys with a relative risk of graft
loss of 1.7 or greater, based on a combination of donor
factors including age, history of hypertension, death from
cerebrovascular accident, and elevated creatinine at the
time of kidney recovery (10). Using this definition, ECD
kidneys constituted only 8% of deceased donor trans-
plants in 1993, but this percentage increased to over 16%
by 1996. In 2002, 15% of deceased donor transplants
were performed with ECD kidneys (Figure 5). As expected,
ECD kidneys had lower deceased donor allograft survival
rates. Unadjusted 3-month, and 1-, 3-, and 5-year deceased
donor kidney allograft survivals were 90%, 81%, 67%, and
51% for recipients of ECD kidneys, compared to 95%,
90%, 81%, and 68% for recipients of non-ECD kidneys,
respectively.
The most appropriate use of expanded criteria donor kid-
neys continues to be debated. In 2002, patients aged
50 years or more and those with diabetic or hypertensive
kidney failure were more commonly transplanted with ECD
kidneys, while sensitized patients and those who had un-
dergone kidney transplantation previously were less likely
to receive them. In addition, only 8% of ECD kidneys were
transplanted to zero antigen mismatched recipients, in con-
trast to 16% of non-ECD kidneys (Table 4). The use of ECD
kidneys in older patients has become progressively more
common over the past decade, with recipients 50 years
of age and older now receiving 70% of ECD kidneys com-
pared to 47% of non-ECD kidneys. It is uncertain whether
this pattern of use is optimal; preliminary evidence sug-
gests that the decrement in transplant survival between

























Source: 2003 OPTN/SRTR Annual Report, Table 5.4. 
Figure 5: Expanded and non-expanded criteria donor kidney trans-
plants, 1993–2002.
Table 4: Distribution of use of expanded criteria donor kidneys,
2002
Donor type
Recipient factor Non-ECD (%) ECD (%)
Age in years
Less than 35 20.1 7.2
65 and over 9.9 22.9
White race 64.3 60.3
Male gender 59.5 60.6
ABO Type O 43.7 46.6
Recipient of previous
kidney transplant 14.5 7.2
Current PRA > 10 15.5 10.6
Peak PRA > 10 31.3 24.2
0 Antigen mismatch 15.6 8.3




Source: 2003 OPTN/SRTR Annual Report, Table 5.4.
Simultaneous Kidney-Pancreas (SPK)
Transplantation
The kidney-pancreas waiting list
The number of potential recipients on the kidney-pancreas
(SPK) transplant waiting list increased from 855 in 1993
to 2425 in 2002; however, the waiting list registration for
SPK transplants has remained stable over the past 3 years
(Figure 6). The majority of registrants were white (80%),
with smaller numbers of African-Americans (18%) and His-
panic/Latino candidates (9%). The percentage of African-
American candidates increased from 13% in 1999 to 18%
in 2002. Since 1993, the proportion of registrations in the
18–34 year age group have declined from 35% to 23%,
while the 50–64 year age group increased from 6% to 17%.
In the 35–49 year age group, the proportion of candidates
has remained stable at about 60% over the past decade.
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There was little change in the gender distribution of the
waiting list over the decade, with 55% of candidates be-
ing male and 45% female in 2002. Twelve percent of the
waiting list had received an organ previously, compared to
20% on the kidney-only waiting list.
Although more patients have been placed on the SPK wait-
ing list, the number of SPK transplants has declined from
a peak of 970 transplants in 1998 to 905 transplants in
2002. This decline may be due to the increasing numbers
of pancreas after kidney (PAK) transplants during this pe-
riod. The lack of increase in SPK procedures has resulted
in increasing waiting times. Until 1997, the median waiting
time was less than a year. Since 1997, the median wait-
ing time has increased, reaching 491 days in 2001. Longer
waiting times are associated with increasing age (584 days
for those aged 50–64 years compared to 470 days for those
aged 18–34 years in 2001). Whites waited a median of
468 days in 2002, less than African-American candidates
(640 days) and Hispanic/Latino candidates (586 days). The
median waiting time for candidates with A and AB blood
types was less than a year for a SPK transplant in 2001;
those with O and B blood types waited 588 days and 548
days, respectively. Previously transplanted candidates ex-
perience twice the waiting time of candidates with no pre-
vious transplants.
The death rate on the waiting list has increased slightly
over the past 10 years, from 76 deaths per 1000 patient
years at risk in 1993 to 86 in 2002. As expected, the risk of
death on the waiting list increased with increasing age. The
death rate in 2002 on the waiting list for candidates aged
18–34 years was 58/1000 patient years at risk, compared
to 114/1000 patient years at risk for ages 50–64.
Kidney-pancreas transplant recipients
There has been little change in SPK recipient characteris-
tics over the past decade; the majority of SPK recipients
are white and/or male. The number of African-American























Source: 2003 OPTN/SRTR Annual Report, Tables 6.1, 7.1, 8.1. 
Figure 6: Patients on the pancreas waiting list, by category, 1993–
2002.
but still only accounted for 12% of total SPK transplants in
2002. Whites accounted for 86% of SPK transplants, down
from 93% in 1993. SPK transplant recipients continued to
have a significant degree of HLA mismatch, with 75% re-
ceiving organs with more than three HLA mismatches.
Outcomes following kidney-pancreas transplantation
Graft survival—kidney. Overall unadjusted kidney graft sur-
vival 1 and 5 years following SPK transplantation were
92% and 74%, respectively. African-Americans had poorer
5-year graft survival than whites or Asians (66%, 75%,
and 82%, respectively). Kidneys from the youngest and
oldest (<5 years and >50 years) donors were associated
with poorer 5-year graft survival; kidneys from donors aged
over 50 years had 64% 5-year graft survival compared to
77% in donors 11–35 years of age. Although few in num-
ber, donors aged 6–10 years exhibited the best 5-year graft
survival (85%). High PRA, retransplantation, and HLA mis-
matching did not appear to be significant long-term risk fac-
tors for graft loss. Male recipient gender was associated
with 6% higher kidney graft survival at 5 years compared
to female gender.
Graft survival—pancreas. Overall, the unadjusted 1- and
5-year pancreas graft survival rates following SPK trans-
plantation were 85% and 70%, respectively (Figure 7). As
noted for kidney graft survival, African-Americans and re-
cipients of organs from older donors experienced poorer
5-year graft survival. For recipients with a previous trans-
plant, there was a 6% lower graft survival at 5 years. HLA
sensitization was also associated with more pancreas graft
loss at 5 years (pancreas graft survival was 70% for unsen-
sitized recipients and 43% for recipients with a current PRA
of 80% or greater).
Simultaneous kidney-pancreas recipient survival. The
death rate in the first year following SPK transplant began
declining in 1995, coinciding with the introduction of my-
cophenolate mofetil and tacrolimus immunosuppression
(13). The death rate declined dramatically from 86/1000 pa-
tient years at risk in 1993 to 52/1000 patient years at risk
in 1999; it has remained below 60 since then and is lower
than the unadjusted death rate among wait-listed candi-
dates. The reduction in deaths occurred despite a shift in
the surgical community to more enteric drained pancreas
transplants, a more technically demanding procedure (14).
Risk factors that confer a higher mortality rate include in-
creasing age, retransplantation, and PRA > 80%.
Unadjusted 1-year patient survival for SPK recipients was
95% and 5-year survival was 84%. Race, ethnicity, gen-
der, PRA, center volume, and level of HLA mismatch were
not associated with increased mortality at 5 years. Of the
8622 SPK transplants performed since 1993, 6544 patients
(76%) were alive at the end of 2002.
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Source: 2003 OPTN/SRTR Annual Report, Tables 6.9, 7.9, 8.9. 
Cohorts are transplants performed during 2000-2001 for 3-month
and 1-year; 1998-1999 for 3-year; and 1996-1997 for 5-year survival.  
Figure 7: Pancreas graft survival among pancreas transplant re-
cipients.
Pancreas after Kidney Transplantation
Pancreas after kidney waiting list
In contrast to the SPK waiting list, the number of patients
awaiting pancreas after kidney (PAK) transplantation con-
tinued to grow, increasing 16% to 781 candidates in 2002
(Figure 6). As with SPK transplants, the majority of PAK can-
didates were 35–49 years old, white and non-Hispanic/non-
Latino. Nearly one-quarter had undergone previous pan-
creas transplantation. Median waiting time increased as
the waiting list grew from 214 days in 1999 to 550 days
in 2001. White and African-American patients experienced
similar waiting times. Females, who constituted only 42%
of the PAK waiting list, waited 110 days longer than males.
The death rate among candidates on the PAK waiting list
was much lower than that seen on the SPK list, ranging
from 24.3 to 34.7 per 1000 patient years at risk from 1999
through 2002.
Pancreas after kidney transplant recipients
The number of PAK transplants also continued to in-
crease, reaching 377 in 2002. Recipient characteristics
mirrored those of candidates on the waiting list.
Most recipients were 35–49 years old (62%), white
(91%), non-Hispanic/non-Latino (94%), and male (58%).
Twenty-one per cent had undergone previous pancreas
transplantation.
Outcomes following pancreas after kidney
transplantation
Graft survival. Pancreas graft survival following PAK trans-
plantation was significantly poorer than that seen following
SPK transplantation, with 1-year unadjusted graft survival
of 79% falling to 46% at 5 years (Figure 7). Recipient age
over 50 years and donor age over 35 years both appear to
reduce graft survival. A consistent effect of HLA mismatch
on graft survival was not observed.
Patient survival. Unadjusted patient survival was similar to
that seen following SPK transplantation until 5 years post-
transplant, when PAK was worse (77%) than SPK (84%).
Older recipient and donor age were also associated with
lower patient survival. Death rates during the first year af-
ter PAK transplantation were higher than that seen among
wait-listed candidates, ranging from 31 to 61 per 1000 pa-
tient years between 1999 and 2002.
Isolated Pancreas Transplantation
The pancreas transplant alone waiting list
The list of candidates awaiting pancreas transplant alone
(PTA) continued to show modest growth, increasing 5%
to 408 in 2002. As with SPK and PAK, the majority of can-
didates were 35–49 years of age (60%), white (94%), and
non-Hispanic/non-Latino (95%). Females, however, consti-
tuted a majority of the PTA waiting list (57%). Only 5%
had previously undergone pancreas transplantation. Wait-
ing times for PTA have tended to be relatively short. Me-
dian waiting time, which ranged from 219 to 343 days be-
tween 1999 and 2000, jumped to 501 days in 2002; the
time by which 25% of candidates were transplanted in-
creased from 62 days in 2000 to 121 days in 2001. The
latter figure dropped to 59 days in 2002, however, sug-
gesting that the prolonged waiting time seen in 2001 may
have been an aberration. The death rate per 1000 patient
years at risk among candidates on the PTA waiting list var-
ied widely from year to year, ranging from 18 to 63 between
1999 and 2002.
Pancreas transplant alone recipients
The number of PTA transplants increased 8% to 175 in
2002. Recipient characteristics were similar to those of
wait-listed candidates. Only five centers reported perform-
ing 10 or more PTA transplants in 2002.
Outcomes following pancreas transplant alone
Graft survival. Graft survival following PTA was similar to
that seen following PAK transplantation (Figure 7). The
number of cases within subgroups makes comparisons
difficult but, as with PAK, there did not appear to be an
effect of HLA matching on either short- or long-term unad-
justed graft survival.
Patient survival. Patient survival was quite good following
PTA, remaining above 90% at 3 years. Death rates during
the first year post-transplant varied widely—from 0 to 39
per 1000 patient years at risk between 1999 and 2002—but
have tended to be lower than those seen among wait-listed
patients, which ranged from 18 to 63 per 1000 patient years
at risk during the same time period.
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